Esperion Therapeutics | ESPR - Gross Profit On Sales


Esperion Therapeutics reported $140.59M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
AbbVie USD 12.54B 474M Mar/2026
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
Amarin USD 23.17M 961K Dec/2025
Amgen USD 6.89B 415M Dec/2025
Biogen USD 1.82B 169.5M Mar/2026
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Cipla INR 39.1B 2.54B Mar/2026
CSL USD 4.46B 2.71B Dec/2025
Cytokinetics USD 19.2M 1.44M Mar/2026
Daiichi Sankyo JPY 439.83B 95.05B Dec/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
Geron USD 50.14M 3.44M Mar/2026
Grifols EUR 766.49M 39.74M Dec/2024
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Ionis Pharmaceuticals USD 243M 48M Mar/2026
Merck USD 10.85B 2.57B Dec/2025
Minerva Neurosciences -4.27M 26.79M Dec/2024
Moderna USD -566M 792M Mar/2026
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Pfizer USD 11.04B 1.24B Mar/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Sanofi EUR 8.45B 1.31B Dec/2025
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
United Therapeutics USD 315.5M 286.6M Dec/2025
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024